How big is Akebia Therapeutics, Inc.?

As of Jun 18, Akebia Therapeutics, Inc. has a market capitalization of 919.23 million and reported net sales of 184.92 million with a net profit loss of 45.31 million over the latest four quarters.

As of Jun 18, Akebia Therapeutics, Inc. has a market capitalization of 919.23 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 184.92 million for the latest four quarters. During the same period, it incurred a net profit loss of 45.31 million.<BR><BR>As of Dec 24, the reporting period for the balance sheet shows shareholder's funds at -49.19 million and total assets amounting to 220.67 million.

What does Akebia Therapeutics, Inc. do?

Akebia Therapeutics, Inc. is a biopharmaceutical company specializing in therapeutics based on hypoxia-inducible factor (HIF) biology, with recent net sales of $57 million and a market cap of $919.23 million. The company is currently loss-making, with a P/E ratio of NA and a dividend yield of 0%.

Overview: <BR>Akebia Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 57 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 6 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 919.23 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 3.69 <BR>Return on Equity: -184.16% <BR>Price to Book: 37.40<BR><BR>Contact Details: <BR>Address: 245 1st St, CAMBRIDGE MA: 02142-1200 <BR>Tel: 1 617 8712098 <BR>Fax: 1 617 8712099 <BR>Website: https://akebia.com/

Who are in the management team of Akebia Therapeutics, Inc.?

As of March 2022, the management team of Akebia Therapeutics, Inc. includes Independent Chairman Mr. Adrian Adams and President/CEO Mr. John Butler, along with several Independent Directors: Mr. Mark Enyedy, Dr. Steven Gilman, Dr. Maxine Gowen, Mr. Michael Heffernan, and Mr. Michael Rogers. They guide the company's strategic direction and operations.

As of March 2022, the management team of Akebia Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Adrian Adams, who serves as the Independent Chairman of the Board.<BR>- Mr. John Butler, who is the President, Chief Executive Officer, and a Director.<BR><BR>Additionally, the Board of Directors features several Independent Directors: <BR>- Mr. Mark Enyedy<BR>- Dr. Steven Gilman<BR>- Dr. Maxine Gowen<BR>- Mr. Michael Heffernan<BR>- Mr. Michael Rogers<BR><BR>This team is responsible for guiding the company's strategic direction and operations.

Should I buy, sell or hold Akebia Therapeutics, Inc.?

Is Akebia Therapeutics, Inc. overvalued or undervalued?

As of March 6, 2017, Akebia Therapeutics, Inc. is considered overvalued and risky due to its high Price to Book Value of 42.42, negative EV to EBIT of -51.46, and troubling ROE of -184.16%, despite a strong year-to-date return of 55.79%.

As of 6 March 2017, the valuation grade for Akebia Therapeutics, Inc. moved from does not qualify to risky, indicating a more cautious outlook. The company appears to be overvalued given its high Price to Book Value of 42.42 and negative EV to EBIT of -51.46, alongside a troubling ROE of -184.16%. In comparison, peers such as Y-mAbs Therapeutics, Inc. have a lower EV to EBITDA of -12.49, and scPharmaceuticals, Inc. shows a more favorable EV to Sales ratio of -4.64, highlighting Akebia's relative weakness in valuation metrics.<BR><BR>Despite a strong year-to-date return of 55.79% compared to the S&P 500's 12.22%, the overall valuation ratios suggest that Akebia is not positioned favorably within its industry. The combination of high valuation ratios and negative returns on equity supports the conclusion that Akebia Therapeutics, Inc. is overvalued.

Is Akebia Therapeutics, Inc. technically bullish or bearish?

As of August 7, 2025, Akebia Therapeutics, Inc. has a mildly bullish trend, supported by daily moving averages, but caution is advised due to mildly bearish weekly MACD and KST indicators, despite outperforming the S&P 500 over the past year.

As of 7 August 2025, the technical trend for Akebia Therapeutics, Inc. has changed from bullish to mildly bullish. The current stance is mildly bullish, supported by daily moving averages indicating a positive trend. However, the weekly MACD and KST are mildly bearish, suggesting some caution. The Bollinger Bands show a mixed signal with weekly mildly bearish and monthly mildly bullish readings. Overall, while the stock has significantly outperformed the S&P 500 over the past year (119.26% vs. 17.14%), recent short-term performance has lagged, with a 1-week return of -1.00% compared to the S&P 500's 1.05%.